Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.
Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.
From molecule to market, our solutions can help.
Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.
Why Us?We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.
SolutionsWe’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.
Track RecordOur experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.
About Us
From computational breakthrough to strategic decision-making – reflections from the World Congress of the International Microsimulation Association I recently attended the World Congress of the International Microsimulation Association (IMA), where researchers from around the world presented the latest advances in microsimulation across multiple fields. One thing immediately stood out. There was remarkably little representation from […]
Read
In many chronic diseases, the challenge is not simply estimating how many patients exist today, it is understanding how those patients will progress over time, and how that progression can be altered. Diseases such as chronic kidney disease (CKD) and other chronic conditions unfold over many years. Patients move through different stages, face different risks, […]
Read
“Prevention, prevention, prevention” – the rallying call from Sandra Gallina, Director General of DG SANTE at the European Commission, set the scene for the core theme that ran through the 10th Politico Health Care Summit in Brussels, on 18th and 19th November. The scale of the challenge The non-communicable disease (NCD) burden across Europe is […]
Read
With the advancement of precision medicine, genetic stratification – dividing patients into subgroups based on their specific mutations – is a key starting point in the drug development lifecycle for rare genetic diseases.
Incorporating a clear stratification plan is a key part of developing an effective Target Product Profile (TPP), which serves as a blueprint for product development by defining what “success” looks like early on, and aligning clinical, regulatory, and commercial strategies to meet patient needs, and regulatory and market requirements.
Read